Found: 6
Select item for more details and to access through your institution.
Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 59, doi. 10.1093/oncolo/oyac142
- By:
- Publication type:
- Article
Loss of ACE2 Exacerbates Murine Renal Ischemia-Reperfusion Injury.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0071433
- By:
- Publication type:
- Article
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4332, doi. 10.1002/cam4.5308
- By:
- Publication type:
- Article
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
- Published in:
- Canadian Journal of Gastroenterology & Hepatology, 2021, p. 1, doi. 10.1155/2021/8811018
- By:
- Publication type:
- Article